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Background: Malignant transformation of hepatocellular adenomas (HCAs) into hepatocellular carcino-
mas (HCCs) has been reported repeatedly and is considered to be one of the main reasons for surgical
treatment. However, its actual risk is currently unknown.
Objective: To provide an estimation of the frequency of malignant transformation of HCAs and to
discuss its clinical implications.
Methods: A systematic literature search was conducted using the following databases: The Cochrane
Hepatobiliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials
(CENTRAL), PubMed, MEDLINE and EMBASE.
Results: One hundred and fifty-seven relevant series and 17 case reports (a total of 1635 HCAs) were
retrieved, reporting an overall frequency of malignant transformation of 4.2%. Only three cases (4.4%) of
malignant alteration were reported in a tumour smaller than 5 cm in diameter.
Discussion: Malignant transformation of HCAs into HCCs remains a rare phenomenon with a reported
frequency of 4.2%. A better selection of exactly those patients presenting with an HCA with an amplified
risk of malignant degeneration is advocated in order to reduce the number of liver resections and thus
reducing the operative risk for these predominantly young patients. The Bordeaux adenoma tumour
markers are a promising method of identifying these high-risk adenomas.
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Introduction
Hepatocellular adenomas (HCAs) are uncommon and essentially
benign tumours in the liver that occur predominantly, but not
exclusively, in young women taking oral contraceptives (OCs).1,2
HCAs are caused by benign proliferation of hepatocytes with high
glycogen and fat content but lack normal hepatic architecture.
They usually present as a solitary nodule that may reach up to
30 cm in diameter.
Clinical manifestations range from asymptomatic presentation
or abdominal pain localized to the epigastric region or right upper
quadrant to a palpable liver mass or even life-threatening haem-
orrhage in the case of rupture.3,4 However, these tumours are most
often encountered as an incidental finding during imaging for
unrelated pathology.
Although the exact pathogenetic mechanism of the deve-
lopment of HCAs remains unknown, an association between
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formation of HCAs and the use of OCs or androgen-containing
anabolic steroids is assumed.5–7 Studies from the past century
suggest that long-term use of OCs increases the annual incidence
of HCAs from 1 per million to 3 to 4 per 100 000.1,8 In addition,
OCs and androgen-containing steroid anabolics have also been
suggested to increase the number and size of these adenomas.
Conversely, HCAs may shown signs of regression on discontinu-
ance of OC use.9,10 HCAs are further reported to be associated
with type I and type III glycogen storage disease (GSD) and,
furthermore, are more likely to be multifocal or to become malig-
nant in these patients.11
The most important complications of HCAs are haemorrhage
and malignant transformation into hepatocellular carcinomas
(HCCs). Thus, these are the two main reasons for surgical treat-
ment. However, little is known about the true incidence, associ-
ated risk factors and the aetiology of malignant alteration of
HCAs. The aim of the current systematic review is to provide an
estimation of the frequency of this phenomenon by means of a
systematic literature search and, moreover, to discuss the clinical
implications.
Methods
Search strategy
A search of all literature up to February 2010 was performed
independently by two investigators (J.H.M.B.S. and R.J.S.C.)
employing all relevant databases including the MEDLINE,
PubMed and EMBASE databases, The Cochrane Hepatobiliary
Group Controlled Trials Register and The Cochrane Central Reg-
ister of Controlled Trials (CENTRAL). Keywords were ‘hepatocel-
lular adenoma’, ‘benign liver tumours’, ‘malignant transformation’
and ‘liver resection’. The search was limited to studies restricted to
humans and articles published from 1970 onwards. This time
period was chosen as the number of reports on hepatocellular
adenomas began rising in the 1970s. All titles and abstracts were
screened and relevant articles were selected.
Study selection criteria
Studies were included if they described a series of patients with
HCAs undergoing surgery, embolization or other (conservative)
treatment. Case reports and imaging studies of these benign
lesions were also included. Only those studies containing a defi-
nite histological diagnosis of the tumours were included. Studies
concerning HCAs in patients with GSD were excluded as these
patients carry a higher risk of developing these lesions and, more-
over, are thought to have an increased risk of malignant degen-
eration. Furthermore, patients with adenomatosis (more than 10
HCAs) were excluded, as this is considered as a different entity.12,13
No further formal quality assessment or selection criteria were
employed.
Data extraction
The reference lists of retrieved articles were reviewed for poten-
tially relevant studies and case reports were also reviewed. When
the full text of an article was not available, an Inter Library Loan
account was used to retrieve these articles from national libraries.
All data of selected articles were screened for duplicate adenoma
cases that had already been reported in prior studies. In the case of
an overlapping series, only the most recent or complete publica-
tion was included. The corresponding author of relevant studies
identified from the initial search, together with experts in the field,
were contacted for any information on unpublished articles and
in case of need for clarification.
Outcome measures and statistical analysis
The main outcome measure was the rate of malignant transfor-
mation. In addition, the numbers of (resected) HCAs, the number
of females, mean age at presentation, mean diameter of the lesion,
OC use and presence of haemorrhage were all assessed. All
reported adenoma cases were listed in a table. All data were
presented as mean or median values and percentages.
Results
A total of 3935 articles were identified through the electronic
searches of PubMed (n = 120), The Cochrane Hepatobiliary
Group Controlled Trials Register and CENTRAL in the Cochrane
Library (n = 12) and a combined Ovid MEDLINE and EMBASE
search (n = 3803). Through reading titles and abstracts 1196
duplicates as well as 2658 noticeably irrelevant articles and eight
articles on GSD or adenomatosis were excluded. Furthermore,
four articles were excluded as they contained a series of adenomas
that had been previously reported. Altogether, 69 articles were
selected for more detailed evaluation. From this analysis, a further
108 studies were included through cross-referencing and three
studies were excluded because of a previously reported series of
adenomas. In total, 174 articles (157 series and 17 case reports) on
liver surgery and imaging, including case series of HCA, were
retrieved (Fig. 1).
Hepatocellular adenoma series in the literature
The 157 series contained a total of 1617 HCAs worldwide, of
which 1445 HCAs (89%) were resected (Table 1). Thirty-six
patients with adenomatosis and 14 patients with GSD were
excluded from a total of eight studies. There were 51 series that
contained only a single patient with HCA. Most of these reports
were published in the 1970s when individual cases of HCA in
women using OCs were regularly reported. The three largest series
contained 91,14 12415 and 12816 HCAs, respectively (patients
having adenomatosis or GSD not included).
Case reports on malignant transformation of
hepatocellular adenomas
The literature search identified 17 case reports concerning malig-
nant transformation (a total of 19 cases), which are presented in
Table 2. The mean age of these patients at the time of surgery was
41 years (range, 19 to 70). Five of these patients (26%) were men,
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of whom one had a history of oral prednisolone use and another
had a history of anabolic steroid use.17,18 Twelve of the 14 women
reported to have malignant alteration of an HCA presented with a
history of OC usage. The mean time elapsed between commence-
ment of OC therapy and diagnosis of HCA was 14 years. Most
cases of malignant transformation of HCAs were seen at the time
of the diagnosis of HCA. Furthermore, only three cases (16%)
among these 19 cases of malignant degeneration presented with
multiple HCAs19–21 and six cases (32%) were complicated by
haemorrhage.21–26
Although some authors noted that HCAs may regress on
discontinuation of oral contraceptive use,9,10,22 three case reports
suggested that even after discontinuation of OC use, HCC can
still develop irrespective of the occurrence of regression of the
HCA.20,22,26 Moreover, the reports by Chuang et al.17 and Colovic
et al.27 showed that malignant transformation of HCAs can occur
in patients without a history of OC use.
Frequency of malignant transformation of
hepatocellular adenomas in the literature
Out of the 1617 HCAs listed in Table 1, 50 tumours (3.1%) under-
went malignant transformation into HCC. By combining these
data with the case reports aforementioned (Table 2), an estima-
tion of the exact frequency of malignant alteration of HCAs could
be made, as the data showed that 68 of a total of 1635 (4.2%)
HCAs underwent malignant transformation. Moreover, of all
resected HCAs (1462 in total), 4.5% contained focal malignancy.
Although not the main scope of the current review, haemorrhage
was found in 406 out of 1635 (25%) tumours, in keeping with
literature data.13,14,28
Association between size of HCA and risk of
malignant transformation
The size of HCA has, by current consensus, remained the main
decision criterion in determining whether or not resection is indi-
cated, based upon the observation that intratumoral bleeding only
seldom takes place in lesions smaller than 5 cm.2,15,29 Concordant
to this observation, most of the resected adenomas identified in
the current search were resected after they reached a minimal size
of 5 cm.4,30 However, limited data was hitherto reported concern-
ing the possibility of an association between the size of HCAs and
the risk of malignant transformation. Particularly, no specific
studies on this subject have been conducted and, moreover, most
series in the literature did not report precise measurements of
the tumours. Nonetheless, some case reports and series of HCAs
with particular diameters were reported. Deneve et al.15 analysed
124 patients with an HCA, of which five cases contained signs of
malignant alteration. The mean size of these five tumours was
 
Potentially relevant articles identified 
through searches of databases 
(n = 3935) 
Articles included in systematic review 
(n = 174) 
- Series (n = 157) 
- Case reports (n = 17) 
Articles retrieved for more detailed 
evaluation 
(n = 69) 
Articles excluded (n = 3866) 
- Irrelevant (n = 2658) 
- Duplicates (n = 1196) 
- GSD or adenomatosis (n = 8) 
- Adenomas reported previously (n = 4) 
- Indefinite histological diagnosis (n = 0) 
Articles excluded (n = 2) 
- Adenomas reported previously (n = 2) 
Potentially appropriate articles to be 
included in systematic review 
(n = 175) 
Articles included through cross-referencing 
(n = 108) 
Articles excluded (n = 1) 
- Adenomas reported previously (n = 1) 
Figure 1 Flowchart literature search. GSD, glycogen storage disease
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Table 1 Overview of series of hepatocellular adenomas with or without malignant transformation into hepatocellular carcinomas
Study Year HCA
(n)
Resected
(n)
HCC
(n)
Female
(n)
Mean
age
(y)
Mean
diameter
(cm)
OC
use
(n)
Haemorrhage
(n)
Embolization
(n)
Smallest
diameter
(cm)a
Malt et al.59 1970 4 3 0 3 – 15.8 – 1 0
Kay and Schatzki60 1971 1 0 0 1 26 10 – 0 0
Horvath et al.61 1972 1 1 0 1 28 15 1 0 0
Motsay and Gamble62 1972 5 5 0 5 30.2 9.6 – 1 0
Baum et al.63 1973 7 7 0 7 – – 7 2 0
Contostavlos64 1973 1 0 0 1 37 15 1 1 0
Davis et al.65 1973 3 3 0 3 25 – – 3 0
Hermann and David66 1973 1 1 0 1 20 12 – 1 0
Albritton et al.67 1974 4 4 0 4 32.8 – – 0 0
Berg et al.68 1974 4 1 0 4 26.5 – 3 3 0
Kelso69 1974 1 1 0 1 36 – 1 1 0
Knapp and Ruebner70 1974 1 1 0 1 33 17 1 1 0
Tountas et al.71 1974 1 1 0 1 30 – 1 1 0
Ameriks et al.72 1975 8 8 0 8 34 15 8 3 0
Antoniades et al.73 1975 1 1 0 1 32 10.8 1 1 0
Antoniades and Brooks74 1975 1 1 0 1 30 6.5 1 1 0
Galloway et al.75 1975 4 1 0 4 41.5 – 1 2 0
Model et al.76 1975 1 1 0 1 31 2.5 1 1 0
Nissen and Kent77 1975 1 1 0 1 27 – 1 1 0
Stenwig and Solgaard78 1975 1 1 0 1 1 31 10 1 1
Ammentorp and Carson79 1976 4 4 0 4 28.8 – 4 0 0
Andersen and Packer80 1976 1 1 0 1 24 4.5 1 1 0
Baek et al.81 1976 1 1 0 1 31 18 1 1 0
Brander et al.82 1976 1 0 0 1 24 – 1 1 0
Edmondson et al.5 1976 42 41 0 42 – – 34 29 0
Lansing et al.83 1976 3 3 0 2 33.7 8.7 1 1 0
Sears et al.84 1976 1 1 0 1 26 10 1 1 0
Chan and Detmer85 1977 4 4 0 4 35.3 11.3 4 2 0
Fechner86 1977 6 5 0 6 30.2 – 5 3 0
Fortner et al.87 1978 1 1 0 – – – – – 0
Gold et al.88 1978 12 7 0 7 30 6,8 6 1 0
Ramseur and Cooper89 1978 1 1 0 1 26 8 1 0 0
Bird et al.90 1979 1 1 0 1 39 15 1 1 0
Cady et al.91 1979 1 1 0 – – – – – 0
Catalano et al.92 1979 4 4 0 4 29 – 4 0 0
Mariani et al.41 1979 1 1 0 1 27 8.5 1 1 0
Wheeler et al.93 1979 1 0 0 1 – – 1 0 1
Weil et al.94 1979 8 8 0 7 24 – 4 4 0
Kelly95 1980 2 1 0 2 30 – 2 1 0
Neuberger et al.96 1980 3 2 1 3 35 – 3 0 0 –
Herczeg et al.97 1981 1 1 0 1 36 – 1 1 0
Isman et al.98 1981 2 2 0 0 41 – – 2 0
Thompson and Little99 1981 1 1 0 1 30 9 1 0 0
Bühler et al.9 1982 3 0 0 3 30.3 6.7 3 1 0
Kerlin et al.100 1983 23 17 2 21 34 9 17 16 0 –
Meensook and Sirisabya101 1983 1 1 0 1 25 16 1 1 0
Thompson et al.102 1983 5 5 0 5 32 – 2 2 0
Cassinelli103 1985 1 1 0 1 38 – 1 0 0
Gonzalez and Marks104 1985 12 12 0 – – – – 2 0
Welch et al.105 1985 13 12 0 12 31 11 9 11 0
Mathieu et al.106 1986 27 27 0 27 34 7.5 26 5 0
Creagh et al.107 1988 1 1 0 0 27 4 1 1 0
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Table 1 Continued
Study Year HCA
(n)
Resected
(n)
HCC
(n)
Female
(n)
Mean
age
(y)
Mean
diameter
(cm)
OC
use
(n)
Haemorrhage
(n)
Embolization
(n)
Smallest
diameter
(cm)a
Leese et al.2 1988 18 17 0 15 33 13 11 9 4
Marks et al.42 1988 3 3 0 3 35.7 – 3 1 0
Ringe et al.108 1989 5 4 0 4 34 10 – 1 0
Flowers et al.109 1990 6 6 0 5 28.8 7.3 5 6 0 –
Iwatsuki et al.110 1990 25 25 0 20 31 12 12 4 0
Leborgne et al.111 1990 2 0 0 2 28 14 2 2 1
Tao47 1991 9 7 0 9 33.5 – 9 0 0 –
Belghiti et al.112 1993 12 12 1 12 33 9.2 11 6 0 –
Arrivé et al.113 1994 29 21 3 27 37.4 5.4 24 15 0 –
Eckhauser et al.114 1994 8 8 0 8 31.5 9.5 7 0 0
Foster and Berman19 1994 13 – 1 12 – – – 1 0 12
Golli et al.115 1994 8 8 0 7 30 6.8 6 1 0
Paineau et al.116 1994 1 1 0 0 – – 0 0 0
Paulson et al.117 1994 9 6 0 8 – – 6 – 0
Pertschy et al.118 1994 30 29 0 – – – – 0 0
Cherqui119 1995 6 6 0 6 32 7.8 5 3 0
Chung et al.110 1995 16 15 0 14 34.6 5.4 5 12 0
Cuesta et al.120 1995 1 1 0 1 56 6 – 0 0
Ferzli et al.121 1995 1 1 0 1 43 9 – – 0
Nagorney122 1995 24 19 1 22 35 9 9 4 0 –
Ault et al.29 1996 11 4 3 10 37.6 – 9 4 4 5.5
Azagra et al.123 1996 1 1 0 1 42 6 – 0 0
Cheng et al.124 1996 1 1 0 1 39 6.4 1 1 0
Kelly et al.125 1996 9 9 0 – – – – 0 0
Vogl et al.126 1996 1 0 0 1 27 – – 0 0
De Carlis et al.127 1997 19 19 2 19 31.8 7.9 17 5 0 –
Krug et al.128 1997 8 8 0 – – – – – 0
Weimann et al.129 1997 41 36 2 – – – – – 0 –
Croes et al.130 1998 8 8 0 8 30 – 6 8 0
Lezoche et al.131 1998 1 0 0 1 – 3 – – 0
Meissner132 1998 1 1 0 1 41 4.5 1 1 0
Ott and Hohenberger133 1998 23 23 0 – – – – 4 0
Katkhouda et al.134 1999 9 9 0 – – – 5 0 0
Closset et al.135 2000 16 16 1 16 35 8.1 10 7 0 15
Herman et al.136 2000 10 10 0 10 29.2 – 9 0 0
Ichikawa et al.137 2000 24 13 2 20 – – 12 10 0 –
Mouiel et al.138 2000 1 1 0 – – – – 0 0
Ji et al.139 2000 4 4 0 1 37 – 0 – 0
Aseni et al.39 2001 1 0 0 1 25 5.5 1 0 0
Charny et al.54 2001 12 8 1 10 34 8.6 – 0 0 –
Heeringa and Sardi140 2001 1 1 0 1 27 5.5 1 1 0
Hung et al.141 2001 12 12 0 6 46.8 5.9 2 4 0
Kammula et al.142 2001 8 8 0 – – – – – –
Mamada et al.143 2001 1 1 0 0 26 4.5 0 0 0
Reddy et al.144 2001 25 25 1 25 33 5.9 21 3 0 25
Terkivatan et al.30 2001 33 19 0 29 36 – 27 12 0
Wilkens et al.145 2001 10 10 0 8 38.9 7.4 – – 0
Antonetti et al.146 2002 1 1 0 – – – – – 0
Farges et al.147 2002 2 2 0 – – – – – 0
Marini et al.148 2002 7 7 1 7 37.4 13.5 0 7 3 –
Croce et al.149 2003 2 2 0 – – – – – 0
Descottes et al.150 2003 17 17 0 – – – – 0 0
Ho et al.151 2003 1 1 0 – – 3.2 – – 0
Morino et al.152 2003 5 5 0 – – – – – 0
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Table 1 Continued
Study Year HCA
(n)
Resected
(n)
HCC
(n)
Female
(n)
Mean
age
(y)
Mean
diameter
(cm)
OC
use
(n)
Haemorrhage
(n)
Embolization
(n)
Smallest
diameter
(cm)a
Clarke et al.153 2004 8 8 0 – – – – – 0
Kim et al.154 2004 11 11 2 – – – – 0 0 –
Liu et al.155 2004 2 2 0 – – – – – 0
Ronald et al.156 2004 3 3 0 0 36 8.3 0 0 0
Atwell et al.57 2005 3 0 0 3 37 3.5 3 2 0
Dulucq et al.157 2005 3 3 0 – – – – 0 0
Geller et al.158 2005 5 5 0 – – – – – 0
Giusti et al.159 2005 1 1 0 0 45 18 0 0 0
Psatha et al.160 2005 4 1 0 0 34.5 7 2 1 0
Socas et al.161 2005 2 0 0 0 29 – 2 1 0
Toso et al.162 2005 23 23 2 – – – – 10 2 6.4
Erdogan et al.58 2006 22 16 0 22 35.8 7.2 17 22 1
Learn et al.163 2006 1 1 0 – – – – – 0
Schemmer et al.164 2006 7 7 0 – – – – – 0
Tang et al.165 2006 1 1 0 – – – – – 0
Vibert et al.166 2006 3 3 0 – – – – – 0
Van der Windt et al.167 2006 48 16 0 48 36 – 45 13 3
Ardito et al.168 2007 7 7 0 – – – – 0 0
Chaib et al.169 2007 28 28 0 24 36.3 8.0 22 3 0
Dagher et al.170 2007 6 6 0 – – – – – 0
Hompes et al.171 2007 2 2 0 – – – – – 0
Ibrahim et al.172 2007 5 5 0 1 37.2 8.1 – 0 0
Koffron et al.173 2007 47 47 0 – – – – – 0
Nissen et al.174 2007 2 2 0 2 46.5 5.3 – 0 0
Poultsides et al.175 2007 1 1 0 1 33 7 – 0 0
Reddy et al.176 2007 25b 25 0 24 38 8.5 15 – 0
Stoot et al.3 2007 11 2 0 10 34 7 9 11 11
Teeuwen et al.177 2007 2 2 0 2 29.5 – 2 0 0
Balaa et al.178 2008 1 1 0 – – – – – 0
Buell et al.179 2008 25 25 0 – – – – – 0
Cho et al.28 2008 41 41 2 38 36 – 22 12 0 5.7
Feng et al.180 2008 17 17 0 – – – – – 0
Machado et al.181 2008 3 3 0 – – – – – 0
Micchelli et al.31 2008 17 17 3 – – – c – 0 4
Petri et al.182 2008 22 22 0 20 38.3 7.7 – – 0
Popescu et al.183 2008 1 1 0 1 38 7.5 – – 0
Pulitano et al.184 2008 7 7 0 – – – – – 0
Spencer et al.185 2008 1 1 0 – – – – – 0
Troisi et al.186 2008 11 11 0 – – – – – 0
Abu Hilal et al.187 2009 8 8 0 – – – – – 0
Al Awad-Jibara et al.188 2009 1 1 0 1 40 5.8 0 0 0
Bioulac-Sage et al.16 2009 128 128 5 116 41 7 106 23 0 –
Bryant et al.189 2009 23 23 0 – – – – – 0
Deneve et al.15 2009 124 119 5 116 39 – 68 31 5 –
Dokmak et al.14 2009 91 91 9 79 – – 70 22 – 2–5
Ito et al.190 2009 5 5 0 – – – – – 0
Machado et al.191 2009 3 3 0 3 – 11.6 – – 0
Skalicky et al.192 2009 9 9 0 – – – – – 0
Tomus et al.193 2009 3 3 0 – – – – – 0
Watkins et al.194 2009 1 1 0 0 45 2.1 0 0 0
Total 1617 1445 50 1075 787 400 35
aSmallest size of HCAs showing malignant transformation.
bThis study contained 2 groups, 25 patients without and 7 with glycogen storage disease (GSD) type Ia, of which the latter was excluded.
cAll cases with malignant transformation included OC use.
HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; Ocs, oral contraceptives; –, no data available or not reported.
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11.6 cm in largest diameter. No tumour smaller than 8 cm showed
malignant transformation in this study. As shown in Table 2, the
mean size of solitary HCAs with features of malignant alteration
reported in the retrieved case reports was 10.5 cm (range 4.5 to
18 cm). Overall, the smallest size at which malignant transforma-
tion was reported in the literature was 4 cm. This malignant alter-
ation occurred in a solitary tumour of a 23-year-old woman who
had taken OCs for 8 years.31 In the series of 91 patients of Dokmak
et al.,14 malignant alteration of either solitary or multifocal HCAs
was seen in nine cases. In this study, only one case of malignant
transformation was observed in an adenoma measuring less
than 5 cm in diameter (2–5 cm, exact size not presented),
concerning a male individual with a history of steroid intake.
Overall, the current literature search showed that a total of three
cases of malignant alteration (4.4% of all HCAs showing this
phenomenon) occurred in a tumour measuring less than 5 cm
in diameter.14,24,31
Discussion
This systematic review has focussed on the risk of malignant
transformation of HCAs into HCCs. The present study shows that
malignant alteration is a rare complication of these uncommon
benign tumours. By performing a systematic search of studies
reporting cases of this benign liver disease over the past 40 years
and combining the data on these HCAs, a total of 1568 reported
HCAs were found. The overall frequency of malignant transfor-
mation reported was 4.2% among all adenoma cases and 4.5%
among all resected HCAs.
Although earlier series of HCAs had already shown one or two
cases, Foster and Berman19 were the first to report an estimated
risk of malignant transformation, as they found a frequency of
13%. Barthelmes and Tait,13 Cho et al.28 and Micchelli et al.31 used
a similar approach for determining the incidence of malignant
degeneration employed in the current study. However, these three
studies identified a remarkably smaller number of case series than
included in the current review, and, moreover, the latter study
did not include cases of HCAs in which no malignant alteration
was found.31 Additionally, most case series used in the frequency
estimation comprised a limited sample size and reported only on
resected adenomas. This could have led to an overestimation of
the true risk, apart from the selection bias of reported studies
and cases in general. The series of Dokmak et al.,14 Deneve et al.15
and Bioulac-Sage et al.16 seem more robust for estimating the
frequency of malignant alteration, as these authors analysed a
larger population containing 91, 124 and 128 patients, respectively
(cases with adenomatosis or GSD not included). Hepatic
adenomatosis is regarded as a different entity by many authors
concerning presentation and size and number of the adenomas,
as well as the different therapeutic options.12,13 Equally, several
Table 2 Overview of reported single cases of malignant transformation of hepatocellular adenomas into hepatocellular carcinomas
Reference Year Age/
gener
Use and
duration
of OCs or
steroids
(years)
Number of HCAs
and size at time
of diagnosis
of HCC
Time to
HCA
diagnosis
(years)a
Interval
between
diagnosis
of HCA
and HCC
(years)
Haemorrhage Resected Outcome
Tesluk and Lawrie26 1981 34/F Yes, 5 Solitary, 16 cm 5 3 Yes Yes Postoperative death after one month
Gordon et al.22 1986 36/F Yes, 14 Solitary, 13 cm 14 3 Yes Yes Disease free
Gyorffy et al.20 1989 53/F Yes, 19 Multiple (3), 12 cm 19 2 No No Tumour-related death after 7 months
Korula et al.195 1991 40/F Yes, 15 Solitary, 6.5 cm 21 None No Yes Disease free
Ferrell196 1993 29/F Yes, 0.5 Solitary, 18 cm 5 None No Yes Disease free
Foster and Bermanb19 1994 56/F Yes, 10 Multiple (3–4) 10 5 No No Tumour-related death after 5 months
Herman et al.197 1994 30/F Yes, 15 – 15 None No Yes n/a
Herman et al.197 1994 37/F Yes, 20 – 20 None No Yes n/a
Perret et al.198 1996 24/F Yes, 3 Solitary, 14 cm 3 None No Yes Disease free
Scott et al.199 1996 22/M No Solitary, 6 cm – None No Yes Disease free
Ye et al.21 1999 42/F Yes, 25 Multiple (2), 9 cm 25 None Yes Yes Disease free
Larson et al.25 2002 52/M No Solitary, 12 cm – 11 Yes Yes Recurrence after 6 years
Chuang et al.17 2002 19/M Yes, 15c – 15 None No Yes n/a
Chuang et al.17 2002 46/F No Solitary, 10 cm – None No Yes n/a
Ito et al.23 2003 57/F Yes, 1 month Solitary, 10 cm 30 None Yes Yes Disease free
Burri et al.200 2006 40/F Yes, 4.5 Solitary, 6 cm 16 None No Yes Disease free
Colovic et al.27 2007 70/F No Solitary, 11.5 cm – None No Yes Disease free
Gorayski et al.18 2008 35/M Yes, 2 Solitary, 9 cm 10 None No Yes Disease free
Kim et al.24 2009 53/M No Solitary, 4.5 cm – None Yes Yes Disease free
aTime to HCA diagnosis since start of oral contraceptive therapy (which may has been discontinued before diagnosis).
bThis case is also enlisted in Table 1.
cOral prednisolone.
HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; Ocs, oral contraceptives; –, no data available or not reported.
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groups have recently reported germ line mutations of hepatocyte
nuclear factor 1a inactivation in adenomatosis, and this has been
suggested to be associated with maturity-onset diabetes of the
young type 3.32–34 Also, these mutations may have implications on
the risk of malignant degeneration. Therefore, and also to limit
heterogeneity, liver adenomatosis was excluded in the present
review. As previously mentioned, patients with known GSDs
are at a higher risk of developing HCAs11,35 and were therefore not
included in the current review.
Risk factors of malignant transformation of
hepatocellular adenomas
Although the risk of malignant transformation seems small
(4.2%), this is a serious complication which cannot be neglected.
As HCAs are difficult to discriminate from HCCs, because of
similar imaging characteristics and histopathological features,
it is important to identify factors that increase the risk of malig-
nant transformation. Unfortunately, in the current study a true
risk analysis based on tumour size was difficult to perform as
many studies only reported the mean size of the adenomas
included. However, as three cases have been reported in which
malignant transformation occurred in a tumour measuring
less than 5 cm in diameter, the recommendation to only treat
HCAs larger than 5 cm in diameter in order to prevent malignant
transformation is open for debate.14,24,31
Upon reviewing the literature, several groups of patients were
identified as having an increased risk of malignant alteration of
these benign liver tumours. High-risk groups reported were those
patients with a history of androgen or anabolic steroid intake,18
patients of male gender14,36 and, as previously stated, patients with
GSD.11,37,38 Furthermore, as has been reported since the late 1970s,
intake of OCs could potentially play a role in the enlargement
of existing HCAs. To date, discontinuation of OC usage is still
the advice given to patients that are diagnosed with an HCA,13 as
several reports showed regression in size of the HCAs after cessa-
tion of OC intake.9,39,40 However, some case reports suggested that
discontinuation of OCs will not abort the risk of malignant trans-
formation.41,42 Therefore, even after discontinuation of OC use,
long-term follow-up of patients with unresected HCAs remains
necessary. Another proposed risk factor for malignant alteration
is the presence of dysplasia in HCAs. This characteristic harbours
a risk of progression to HCC.43–47
Several studies have identified mutations of the b-catenin gene
in HCAs and reported that activated b-catenin mutations deregu-
late the b-catenin pathway. This pathway is part of the more
complex Wnt signalling pathway which plays a major role in the
proliferation of liver cells.36,48–50 These mutations may thus lead
to hyperproliferation of liver cells and, consequently, malignancy.
The Bordeaux group has performed genotype–phenotype analy-
ses in HCAs and identified four different tumour subtypes with
specific characteristics: (i) hepatocyte nuclear factor 1a (HNF1a)
mutated (30%–50%), (ii) b-catenin-activated (10–15%), (iii)
inflammatory (35%) and (iv) unclassified tumours (5%–
10%).36,51,52 Hepatocellular carcinoma associated with adenoma
was found in 46% of b-catenin-mutated tumours, whereas this
has never been observed in inflammatory lesions and rarely found
in HNF1a-mutated tumours. This suggests that HCAs with
b-catenin activation carry a higher risk of malignant transforma-
tion. Furthermore, the Bordeaux group identified four immuno-
histochemical markers that characterize each of the four HCA
subtypes with high specificity and sensitivity: liver-fatty acid
binding protein (L-FABP), glutamine synthetase (GS), nuclear
b-catenin and serum amyloid A (SAA).53 They found absence of
L-FABP expression to indicate HNF1a mutation, whereas com-
bined GS overexpression and nuclear b-catenin staining suggested
b-catenin-activating mutations. Finally, the Bordeaux group
noted that SAA staining and overexpression of C-reactive protein
(CRP) predicted inflammatory HCA. These markers have proven
to be a promising method to identify adenoma patients at risk of
developing HCC. Table 3 provides an overview of HCA subtypes
and their immunohistochemical markers.
Future treatment perspectives
As for future treatment perspectives, more research is needed to
investigate the mechanism of malignant degeneration. Only then
can this group of predominantly young patients be withheld a
potentially unnecessary liver resection, while this surgical treat-
ment has still a reportedmorbidity andmortality of up to 27% and
3%, respectively.30,54–56 At present, for all patients presenting with
one or more HCAs larger than 5 cm, resection is the treatment
option of choice in accordance with the current guidelines. Only
4.2% of HCAs will have actual foci of HCC, and therefore a
considerable number of resections will be performed in vain.
However, this rate should preferably be seen as anupper limit of the
true frequency as publication bias might have occurred. After all,
men who have an anabolic steroid-induced adenoma containing
foci of malignancy are more likely to be reported in the literature
than those adenoma patients without malignant transformation.
Nevertheless, over 95% of all patients presenting with HCAs mea-
suring over 5 cm, will unnecessarily be exposed to a potentially
hazardous surgical procedure. By identifying those patients who
will derive most benefit from surgery as their HCA harbours an
increased risk for malignant alteration, fewer patients will have to
undergo this unnecessary surgery. The BordeauxHCAmarkers are
Table 3 Types of HCAs and their immunohistochemical markers
HCA type Frequency
(%)
Malignant
transformation
Markers
b-catenin activated 10–15 Yes b-catenin+/GS+
HNF1a inactivated 30–50 Rarely LFABP-
Inflammatory 35 No SAA+/CRP+
Unclassified 5–10 No None
CRP, C-reactive protein; GS, glutamine synthetase; HCA, hepatocellular
adenoma; HNF1a, hepatocyte nuclear factor 1a; LFABP, liver-fatty acid
binding protein; SAA, serum amyloid A; +, positive; -, negative.
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a promising risk prediction tool. However, biopsy could lead to
haemorrhage, sample errors or tumour seeding,but these potential
complications are rare in experienced centres. Also, the value of
b-catenin staining needs to be studied more intensively. Recently,
interest has turned towards less invasive procedures to treat
patients that present withHCAs larger than 5 cm.There is prelimi-
nary evidence to suggest that developments in minimally invasive
techniques such as (percutaneous) radiofrequency ablation (RFA)
ormicrowave ablationmay alter the treatment of HCA.The limited
data so far available suggest that these techniques can be performed
with low morbidity and zero mortality, but additional research is
required to explore their exact role in adenoma treatment.57
Recently, two groups have reported the therapeutic effects of
selective arterial embolization to stop haemorrhaging from rup-
tured adenomas.3,58 They also showed that embolizing ruptured
adenomas prevented growth of these lesions. Subsequently, selec-
tive arterial embolization was utilized in a number of non-
haemorrhaging adenomas.3 During follow-up, none of these
adenomas grew and the majority even regressed in size. On exam-
ining the haemorrhaging and non-haemorrhaging adenomas
separately, a statistically significant decrease in size was noted
in both groups. It is this tumour regression, and its probable
subsequent reduction of the risk of severe haemorrhaging and
malignant transformation, that might propose selective arterial
embolization as a novel treatment for large unruptured HCAs. As
no significant complications from this treatment were reported
arterial embolization of HCAs might be the direction for further
future research.3,58 To the best of our knowledge, no studies have
been performed to specifically investigate this treatment.
In conclusion, the current review shows that malignant trans-
formation of HCAs into HCCs is a rare complication of these
uncommon benign tumours. By pooling data of series and case
reports, comprising more than 1600 reported HCAs, we found an
overall frequency of malignant transformation of 4.2% for all
adenomas and of 4.5% for all resected adenomas. A multicentre
study with a large registry of HCAs is paramount for estimating
the actual risk of malignant transformation. Further research
should focus on the underlying mechanisms of malignant trans-
formation of HCAs into HCCs, associated risk factors and the use
of new tumourmarkers. Bymeans of a better selection of precisely
which patients with an HCA present with an increased risk of
malignant degeneration – and who could therefore derive the
greatest benefit from treatment – a reduction in unnecessary liver
resections can be achieved. This would reduce the risks associated
with surgery in these predominantly young patients.
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